These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32909731)

  • 1. Rapid, Cost-Effective Peptide/Nucleic Acid-Based Platform for Therapeutic Antibody Monitoring in Clinical Samples.
    Mocenigo M; Porchetta A; Rossetti M; Brass E; Tonini L; Puzzi L; Tagliabue E; Triulzi T; Marini B; Ricci F; Ippodrino R
    ACS Sens; 2020 Oct; 5(10):3109-3115. PubMed ID: 32909731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmable Nucleic Acid Nanoswitches for the Rapid, Single-Step Detection of Antibodies in Bodily Fluids.
    Porchetta A; Ippodrino R; Marini B; Caruso A; Caccuri F; Ricci F
    J Am Chem Soc; 2018 Jan; 140(3):947-953. PubMed ID: 29313682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab quantification in serum: a new, rapid, robust ELISA assay based on a mimetic peptide that specifically recognizes trastuzumab.
    Cardinali B; Lunardi G; Millo E; Armirotti A; Damonte G; Profumo A; Gori S; Iacono G; Levaggi A; Del Mastro L
    Anal Bioanal Chem; 2014 Jul; 406(18):4557-61. PubMed ID: 24828979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.
    Damen CW; Derissen EJ; Schellens JH; Rosing H; Beijnen JH
    J Pharm Biomed Anal; 2009 Dec; 50(5):861-6. PubMed ID: 19487098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab.
    Agnolon V; Contato A; Meneghello A; Tagliabue E; Toffoli G; Gion M; Polo F; Fabricio ASC
    Sci Rep; 2020 Feb; 10(1):3016. PubMed ID: 32080226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
    Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
    Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting.
    Westerlund K; Vorobyeva A; Mitran B; Orlova A; Tolmachev V; Karlström AE; Altai M
    Biomaterials; 2019 May; 203():73-85. PubMed ID: 30877838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme - Switch sensors for therapeutic drug monitoring of immunotherapies.
    Campbell E; Adamson H; Kohl D; Tiede C; Wälti C; Tomlinson DC; Jeuken LJC
    Biosens Bioelectron; 2023 Oct; 237():115488. PubMed ID: 37419072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
    Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
    BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microfabricated calorimeters for thermometric enzyme linked immunosorbent assay in one-Nanoliter droplets.
    Lubbers B; Kazura E; Dawson E; Mernaugh R; Baudenbacher F
    Biomed Microdevices; 2019 Aug; 21(4):85. PubMed ID: 31451947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
    Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of ELISA for herceptin detection in human serum.
    Maple L; Lathrop R; Bozich S; Harman W; Tacey R; Kelley M; Danilkovitch-Miagkova A
    J Immunol Methods; 2004 Dec; 295(1-2):169-82. PubMed ID: 15627622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
    Chen KT; Lee TW; Lo JM
    Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
    Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
    Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer.
    Arteaga CL
    Breast Cancer Res; 2003; 5(2):96-100. PubMed ID: 12631388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
    Scollard DA; Chan C; Holloway CM; Reilly RM
    Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.
    Hudelist G; Köstler WJ; Czerwenka K; Kubista E; Attems J; Müller R; Gschwantler-Kaulich D; Manavi M; Huber I; Hoschützky H; Zielinski CC; Singer CF
    Int J Cancer; 2006 Mar; 118(5):1126-34. PubMed ID: 16161043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.